Last 48 quarters of trend data · Healthcare · Medical - Instruments & Supplies
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
Nephros, Inc.'s quarterly P/E stands at 74.5x, up 811.3% year-over-year — indicating the stock has re-rated higher or earnings have softened. EV/EBITDA has expanded 821.4% YoY to 58.9x, reflecting rising market expectations or slowing EBITDA growth.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 32.00 | 74.50 | 221.82 | 38.77 | 46.69 | 8.17 | 11.10 | 24.71 | — | — | — | — | — |
| — | +811.3% | +1897.9% | +56.9% | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 2.03 | 1.57 | 2.83 | 2.74 | 2.50 | 0.94 | 1.00 | 1.29 | 1.70 | 1.63 | 2.80 | 1.03 | 1.13 |
| — | +67.8% | +182.3% | +113.1% | +46.8% | -42.7% | -64.2% | +24.3% | +51.5% | +119.1% | +140.1% | +6.3% | -18.6% | |
| P/B Ratio | 3.78 | 3.06 | 5.25 | 5.22 | 4.61 | 1.97 | 1.81 | 2.21 | 2.80 | 2.81 | 4.36 | 1.80 | 1.84 |
| — | +55.7% | +190.3% | +135.8% | +64.7% | -30.1% | -58.6% | +23.3% | +51.7% | +127.0% | +224.5% | +83.5% | +46.1% | |
| P/FCF | 23.23 | — | 58.18 | 131.88 | 11.12 | 14.18 | 2.97 | — | — | — | — | 6.89 | 17.66 |
| — | — | +1855.6% | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | 26.34 | 58.93 | 250.95 | 34.63 | 35.68 | 6.40 | 9.33 | 17.84 | — | — | — | — | — |
| — | +821.4% | +2590.9% | +94.1% | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | 29.56 | — | 12296.79 | 35.45 | 40.88 | 6.95 | 9.04 | 23.40 | — | — | — | — | — |
| — | — | +135863.7% | +51.5% | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Nephros, Inc.'s operating margin was 1.9% in Q1 2026, up 1.5 pp QoQ and down 9.7 pp YoY. The trailing four-quarter average of 3.6% exceeds the current quarter, suggesting the latest result may reflect seasonal weakness or a one-off headwind. Gross margin contracted 11.2% YoY, suggesting cost inflation or competitive pricing pressure.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 61.1% | 57.4% | 55.4% | 61.2% | 63.2% | 64.7% | 64.0% | 61.1% | 58.8% | 62.1% | 62.1% | 58.6% | 56.8% |
| — | -11.2% | -13.3% | +0.2% | +7.6% | +4.1% | +3.0% | +4.2% | +3.5% | +8.7% | +5.3% | +85.4% | +16.1% | |
| Operating Margin | 6.1% | 1.9% | 0.4% | 6.6% | 5.6% | 11.6% | 8.2% | 5.9% | -9.7% | -5.7% | -19.9% | -5.4% | -12.3% |
| — | -84.0% | -95.4% | +12.6% | +157.6% | +304.4% | +141.1% | +207.9% | +20.6% | +31.4% | +26.4% | +89.8% | +57.0% | |
| Net Margin | 6.4% | 2.7% | 1.3% | 7.1% | 5.4% | 11.4% | 9.0% | 5.2% | -8.9% | -4.8% | -20.1% | -4.9% | -12.2% |
| — | -76.5% | -85.5% | +36.0% | +160.4% | +338.4% | +144.9% | +207.0% | +27.2% | +42.0% | +44.0% | +96.4% | +71.1% |
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 12.7% | 1.3% | 0.6% | 3.4% | 2.5% | 6.2% | 4.2% | 2.3% | -3.6% | -2.0% | -7.7% | -2.1% | -4.9% |
| — | -78.5% | -85.3% | +51.2% | +169.9% | +405.5% | +154.1% | +207.9% | +27.3% | +40.6% | +22.5% | +92.8% | +46.9% | |
| ROA | 9.6% | 1.0% | 0.5% | 2.6% | 2.0% | 4.9% | 3.2% | 1.7% | -2.6% | -1.5% | -5.7% | -1.7% | -4.1% |
| — | -79.0% | -85.7% | +55.2% | +176.9% | +434.3% | +156.3% | +199.7% | +36.8% | +48.0% | +30.2% | +93.0% | +48.5% | |
| ROIC | 14.2% | 1.1% | 0.2% | 4.0% | 3.0% | 6.6% | 3.5% | 2.3% | -3.7% | -2.5% | -9.1% | -3.0% | -5.7% |
| — | -83.8% | -93.6% | +76.8% | +180.6% | +369.0% | +138.8% | +176.1% | +34.3% | +33.6% | -10.2% | +76.2% | +15.3% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
Nephros, Inc.'s Debt/EBITDA ratio is 7.7x, down from 21.7x last quarter — elevated, raising questions about debt serviceability. The current ratio has weakened 23.2% YoY to 4.55x, tightening the short-term liquidity position. Debt/Equity has declined for 10 consecutive quarters, reflecting a deleveraging trend.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.10 | 0.09 | 0.10 | 0.12 | 0.13 | 0.14 | 0.16 | 0.18 | 0.20 | 0.21 | 0.22 | 0.09 | 0.10 |
| — | -36.7% | -36.6% | -36.8% | -35.1% | -31.6% | -25.2% | +101.8% | +101.3% | +99.6% | +78.5% | +51.3% | +41.1% | |
| Debt / EBITDA | 0.83 | 7.68 | 21.69 | 3.32 | 4.39 | 2.19 | 4.00 | 6.22 | — | — | — | — | — |
| — | +250.8% | +442.7% | -46.7% | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 4.06 | 4.55 | 4.06 | 4.34 | 5.41 | 5.92 | 5.31 | 6.95 | 4.06 | 4.21 | 3.98 | 4.65 | 6.61 |
| — | -23.2% | -23.7% | -37.6% | +33.1% | +40.5% | +33.6% | +49.4% | -38.6% | -28.4% | -32.0% | -20.8% | +25.5% | |
| Quick Ratio | 2.89 | 3.12 | 2.89 | 3.23 | 4.14 | 4.64 | 3.64 | 4.02 | 2.62 | 2.77 | 2.81 | 3.41 | 4.84 |
| — | -32.8% | -20.6% | -19.7% | +57.9% | +67.1% | +29.5% | +17.9% | -45.7% | -34.3% | -22.4% | -6.0% | +58.1% | |
| Interest Coverage | 1146.00 | — | — | — | 247.00 | — | — | — | — | -168.00 | -653.00 | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorDCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare business quality, growth, and profitability against top sector peers.
Start ComparisonQuick answers to the most common questions about buying NEPH stock.
Nephros, Inc.'s current P/E is 32.0x. The average P/E over the last 4 quarters is 95.4x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Nephros, Inc.'s current operating margin is 6.1%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Nephros, Inc.'s business trajectory between earnings reports.